Michael W. Buchanan
About Michael W. Buchanan
Michael W. Buchanan is a Supervisor of Clinical Manufacturing at Kite Pharma, where he has worked since 2021. He has extensive experience in cell therapy and biotech production, having previously held various roles at Kite Pharma and Regeneron Pharmaceuticals.
Current Role at Kite Pharma
Michael W. Buchanan serves as Supervisor of Clinical Manufacturing at Kite Pharma, a position he has held since 2021. In this role, he oversees clinical manufacturing operations, ensuring compliance with regulatory standards and optimizing production processes. His responsibilities include managing teams and coordinating the production of cell therapies, contributing to the advancement of immuno-oncology therapies.
Previous Experience at Kite Pharma
Buchanan has held multiple positions at Kite Pharma, starting as a Cell Therapy Specialist I from 2018 to 2020, followed by a role as Cell Therapy Specialist II/III from 2020 to 2021. He transitioned to Technical Manufacturing Specialist I for a six-month period in 2021. His experience at Kite Pharma has provided him with a comprehensive understanding of the manufacturing processes involved in cell therapy.
Experience at Regeneron Pharmaceuticals
Before joining Kite Pharma, Michael W. Buchanan worked at Regeneron Pharmaceuticals, Inc. as a Biotech Production Specialist II from 2016 to 2018. In this role, he gained valuable experience in biotech production, which contributed to his expertise in the field of clinical manufacturing and production processes.
Educational Background
Buchanan earned a Bachelor of Science (B.S.) degree in Chemistry from Penn State University, where he studied from 2011 to 2015. During his time at the university, he also worked as an Undergraduate Researcher for seven months in 2015, gaining hands-on experience in research methodologies and laboratory practices.
Skills and Expertise
Michael W. Buchanan possesses strong professional operation skills, particularly in small scale cGMP production suites. His expertise extends to advancing the development of immuno-oncology therapies, reflecting his commitment to improving patient outcomes through innovative therapeutic approaches.